Precis Future Med.
2023 Jun;7(2):74-82. 10.23838/pfm.2023.00051.
Comparison of survival outcomes between de novo and recurrent stage IV gastric cancers: A retrospective cohort study
- Affiliations
-
- 1Division of Hematology and Oncology, Department of Internal Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Korea
- 2Karsh Division of Gastroenterology and Hepatology, Comprehensive Transplant Center, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA
- 3Department of Internal Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Korea
- 4Department of Surgery, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Korea
- 5Department of Research Support, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Korea
- 6Department of Nursing, Sungkyunkwan University School of Medicine, Changwon, Korea
- 7Department of Internal Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA
- 8Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA
- 9Department of Gastroenterology, Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
- KMID: 2543582
- DOI: http://doi.org/10.23838/pfm.2023.00051
Abstract
- Purpose
This study analyzes the characteristics and prognosis of patients with de novo and recurrent metastatic gastric cancers.
Methods
This retrospective study included 301 advanced, pathologically confirmed gastric cancer patients who received palliative chemotherapy between 2012 and 2022. The de novo cohort included patients who presented with distant metastasis at diagnosis, and the recurrent metastatic cohort was composed of patients with metastasis after curative gastrectomy. We analyzed prognostic association by Cox regression and compared survival time of both cohorts using the Kaplan-Meier survival analysis.
Results
The study included 167 de novo and 112 recurrent patients. No differences were noted among the patients with de novo disease and recurrent metastatic disease concerning age, sex, Eastern Cooperative Oncology Group scores, primary cancer location, and pathologic features. Patients in the recurrent group versus the de novo group had a longer duration of chemotherapy (1.16±1.18 years vs. 0.85±0.84 years, P= 0.01) and lower mean body mass index (20.22±2.78 kg/m2 vs. 21.93±3.38 kg/m2, P< 0.001). The median overall survival in the de novo group was 11.6 versus 14.4 months in the recurrent group (P= 0.02).
Conclusion
De novo and recurrent metastatic gastric cancer are characterized by distinct subpopulations. Advanced gastric cancer patients with recurrence have significantly better survival versus those in the de novo cohort. The differences between de novo and recurrent gastric cancer patient outcomes could facilitate discussions about the selection of the clinical trial of each patient and help with their personalized treatment.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Different Clinical Outcomes of Stage IV Gastric Cancer according to the Curability of Surgery
- Subclassification of Stage IV Gastric Cancer According to the Presence of Distant Metastasis (IVa and IVb)
- Clinicopathological Analysis of Borrmann Type IV Gastric Cancer
- Retrospective Analysis of Treatment Results of Recurrent Gastric Cancer
- Total Gastrectomy for Gastric Cancer Involving the Cardia
